Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoflurane for Treatment Resistant Depression
NCT04171193Phase 2Unknown
- Sponsor
- Universidade de São Paulo
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of isoflurane in major depressive disorder (MDD), sponsored by Universidade de São Paulo. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 7 weeks. Status: unknown.
02
Drugs
isoflurane
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04171193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171193.